55 results found.

Brain and Central Nervous System Tumors, Cognitive/Functional Eff Clinical Trial using modafinil; placebo

University of South Florida - Recruiting 6 years to 17 years.
- A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor.
modafinil; placebo

Glioblastoma, or Recurrent Metastatic Cancer to the Brain Clinical Trial using ExAblate 4000

InSightec - Recruiting 18 years to 70 years.
- A Feasibility Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Lesions.
ExAblate 4000

Recurrent Melanoma, Stage IV Melanoma, or Tumors Metastatic to Br Clinical Trial using Ipilimumab; Whole-Brain Radiation Therapy (WBRT); Stereotactic Radiosurgery (SRS)

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases.
Ipilimumab; Whole-Brain Radiation Therapy (WBRT); Stereotactic Radiosurgery (SRS)

Glioma, or Metastatic Brain Cancer Clinical Trial using ExAblate Transcranial System

InSightec - Recruiting 18 years to 75 years.
- A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors.
ExAblate Transcranial System

Brain and Central Nervous System Tumors, Intraocular Melanoma, Lu Clinical Trial using DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms.
DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Malignant Glioma Clinical Trial using 18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide

Dr. Negrin University Hospital - Recruiting 18 years to 75 years.
- Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation.
18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide

Solid Tumors, Brain Tumors, Sarcoma, Wilm's Tumor, or Rhabdomyosa Clinical Trial using NK cellular therapy; rhIL-15

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 29 years.
- A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors.
NK cellular therapy; rhIL-15

Astrocytoma, Central Nervous System Tumor, Glioblastoma, Glioma, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year or older.
- Evaluation of the Natural History of Patients With Tumors of the Central Nervous System.

Pediatric Cancer, Leukemia, Sarcoma, or Brain Tumors Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 18 years.
- Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group.

Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, or Brain Tumo Clinical Trial using plerixafor

Sanofi - Recruiting 1 year to 18 years.
- A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to <18 Years, With Solid Tumours Eligible for Autologous Transplants..
plerixafor

Neuroblastoma, Medulloblastoma, Brain Tumors, or Rare Tumors Clinical Trial using Guided Therapy- Pediatric Gene Analysis Platform

Spectrum Health Hospitals - Recruiting 13 Months or older.
- A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer.
Guided Therapy- Pediatric Gene Analysis Platform

Brain and Central Nervous System Tumors Clinical Trial

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas and Medulloblastoma/PNET of the Pediatric CNS.

Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourin Clinical Trial using IGF-Methotrexate

University of Illinois at Chicago - Recruiting 18 years or older.
- STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R.
IGF-Methotrexate

Brain and Central Nervous System Tumors Clinical Trial using polymorphism analysis; laboratory biomarker analysis; medical chart review

University of California, San Francisco - Recruiting 18 years or older.
- San Francisco Bay Area Adult Glioma Prognosis Study Protocol.
polymorphism analysis; laboratory biomarker analysis; medical chart review

Brain and Central Nervous System Tumors Clinical Trial using mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment.
mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study

Neoplasms, Brain Clinical Trial using Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

GlaxoSmithKline - Recruiting 1 Month to 17 years.
- Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation Positive Solid Tumors.
Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

Tumors Metastatic to Brain, or Unspecified Adult Solid Tumor Clinical Trial using stereotactic radiosurgery; quality-of-life assessment; cognitive assessment

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- Dose Escalation for Larger Brain Metastases: Phase I/II Study.
stereotactic radiosurgery; quality-of-life assessment; cognitive assessment

Tumors Metastatic to Brain Clinical Trial using radiosurgery; therapeutic conventional surgery; quality-of-life assessment

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study.
radiosurgery; therapeutic conventional surgery; quality-of-life assessment

Glioblastoma, Malignant Glioma, Brain Tumors, or Anaplastic Astro Clinical Trial using Stem Cell Radiotherapy (ScRT) and Temozolomide

Beth Israel Medical Center - Recruiting 18 years to 70 years.
- STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial.
Stem Cell Radiotherapy (ScRT) and Temozolomide

Primary Brain Tumors, or Secondary Brain Tumors Clinical Trial using 4-Demethyl-4-cholestryloxycarbonylpenclomedine

DEKK-TEC, Inc. - Recruiting 18 years or older.
- A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System.
4-Demethyl-4-cholestryloxycarbonylpenclomedine

Brain Neoplasms, or Surgery Clinical Trial using dexmedetomidine; normal saline

China Medical University, China - Recruiting 35 years to 65 years.
- Randomized, Parallelled and Double-blinded Trial of Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia.
dexmedetomidine; normal saline

Brain Tumor Clinical Trial using MRI

University of Texas Southwestern Medical Center - Recruiting 18 years or older.
- High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors.
MRI

Brain and Central Nervous System Tumors Clinical Trial using carboplatin; tamoxifen citrate; temozolomide; adjuvant therapy; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas.
carboplatin; tamoxifen citrate; temozolomide; adjuvant therapy; radiation therapy

Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, or Malign Clinical Trial using 2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

to-BBB technologies B.V. - Recruiting 18 years or older.
- An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

Brain and Central Nervous System Tumors, Neuroblastoma, or Sarcom Clinical Trial using iodine I 131 monoclonal antibody 8H9

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms.
iodine I 131 monoclonal antibody 8H9

High Grade Glioma Clinical Trial using FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

Brigham and Women's Hospital - Recruiting 18 years to 85 years.
- Personalized Translational Platform for Biomarker Discovery in Brain Tumors.
FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

Tumors Metastatic to Brain Clinical Trial using sorafenib tosylate; stereotactic radiosurgery; laboratory biomarker analysis

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients With 1-4 Brain Metastases.
sorafenib tosylate; stereotactic radiosurgery; laboratory biomarker analysis

Malignant Glioma, or Recurrent Ependymoma Clinical Trial using AdV-tk; valacyclovir; Radiation

Advantagene, Inc. - Recruiting 3 years to 21 years.
- A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors.
AdV-tk; valacyclovir; Radiation

Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, B Clinical Trial using 5-ALA (Gliolan)

Emory University - Recruiting 18 years or older.
- WCI1999-11: A Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas.
5-ALA (Gliolan)

Glioblastoma Clinical Trial using Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)

Michigan State University - Recruiting 18 years to 90 years.
- Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors.
Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)

Brain Tumor, or Malignant Neoplasm of Fourth Ventricle of Brain Clinical Trial using Ommaya Reservoir; Methotrexate; Leucovorin

M.D. Anderson Cancer Center - Recruiting N/A to 22 years.
- Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study.
Ommaya Reservoir; Methotrexate; Leucovorin

Brain Tumors, Brain Aneurysms, or Brain AVMs Clinical Trial using Nicardipine or Esmolol

Northwestern University - Recruiting 18 years or older.
- Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy.
Nicardipine or Esmolol

Brain and Central Nervous System Tumors Clinical Trial using olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery

Cancer Research UK - Recruiting 18 years to 70 years.
- A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.
olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery

Brain Tumor Clinical Trial using Exercise Program

The Hospital for Sick Children - Recruiting 9 years to 14 years.
- The Neuro-protective Effects of Exercise in Children With Brain Tumors.
Exercise Program

Brain and Central Nervous System Tumors, Chronic Myeloproliferati Clinical Trial using 3'-deoxy-3'-[18F]fluorothymidine

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET).
3'-deoxy-3'-[18F]fluorothymidine

Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, or Hi Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 1 year to 30 years.
- A Phase I Study of Dendritic Cell Vaccine Therapy With In Situ Maturation for Pediatric Brain Tumors.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

Brain and Central Nervous System Tumors Clinical Trial using hydroxyurea; imatinib mesylate

National Cancer Institute (NCI) - Recruiting 18 years to 75 years.
- IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study.
hydroxyurea; imatinib mesylate

Primary Central Nervous System Lymphoma, Brain and Central Nervou Clinical Trial using Rituxan; Carboplatin; Methotrexate; Sodium thiosulfate; Neupogen; Neulasta; Leucovorin

OHSU Knight Cancer Institute - Recruiting 18 years to 75 years.
- A Phase I/II Study of Patient With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen.
Rituxan; Carboplatin; Methotrexate; Sodium thiosulfate; Neupogen; Neulasta; Leucovorin

Brain Tumors Clinical Trial using DC/AAT; DC/AAT-Flu; DC/KLH

Rockefeller University - Recruiting 18 years or older.
- A Phase I Study of Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells (DC/AAT) Administered Intradermally to Cancer Patients With Brain Tumors.
DC/AAT; DC/AAT-Flu; DC/KLH

Central Nervous System (CNS) Metastases, or Brain Metastases Clinical Trial using Topotecan; Temozolomide

The Methodist Hospital System - Recruiting 18 years to 79 years.
- Phase II Trial of Chemotherapy With Temozolomide in Combination With Topotecan for Central Nervous System (CNS) Metastasis of Solid Tumors.
Topotecan; Temozolomide

Brain and Central Nervous System Tumors Clinical Trial using dasatinib; temozolomide; placebo

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
dasatinib; temozolomide; placebo

Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, or Brain Clinical Trial using Marqibo

Spectrum Pharmaceuticals, Inc - Recruiting 2 years to 20 years.
- Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer.
Marqibo

Brain and Central Nervous System Tumors Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A to 18 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens.
biologic sample preservation procedure

Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Clinical Trial using crizotinib; pharmacogenomic studies; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study

Brain and Central Nervous System Tumors Clinical Trial using cisplatin; cyclophosphamide; etoposide; lomustine; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 3 years to 30 years.
- Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma).
cisplatin; cyclophosphamide; etoposide; lomustine; vincristine sulfate

Brain and Central Nervous System Tumors Clinical Trial using temozolomide; DNA methylation analysis; laboratory biomarker analysis; adjuvant therapy; quality-of-life assessment; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial..
temozolomide; DNA methylation analysis; laboratory biomarker analysis; adjuvant therapy; quality-of-life assessment; radiation therapy

Brain Tumors Clinical Trial using MRI

University of Michigan - Recruiting 18 years or older.
- Quantitation of Human Brain Tumor Therapy Response by MR.
MRI

Primary Glial Neoplasms of Brain, or Glioblastoma Clinical Trial using Aminolevulinic Acid

West Penn Allegheny Health System - Recruiting 18 years or older.
- A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain..
Aminolevulinic Acid

Palliative Care, or Communication Clinical Trial

Barnes-Jewish Hospital - Recruiting 18 years or older.
- Timely End-of-Life Communication to Parents of Children With Brain Tumors.

Brain Tumor Clinical Trial using high-dose chemotherapy and autologous stem cell rescue

Samsung Medical Center - Recruiting N/A or older.
- Multicenter Clinical Trial to Evaluate Efficacy of High-dose Chemotherapy With Autologous Stem Cell Rescue for Children With High-risk Brain Tumors.
high-dose chemotherapy and autologous stem cell rescue

Neuroblastoma, Brain Tumors, or Solid Tumors Clinical Trial using Temozolomide/Hycamtin (Topotecan)

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 6 Months to 20 years.
- Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours.
Temozolomide/Hycamtin (Topotecan)

Brain and Central Nervous System Tumors Clinical Trial using antineoplaston A10; antineoplaston AS2-1

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma.
antineoplaston A10; antineoplaston AS2-1

Brain and Central Nervous System Tumors Clinical Trial using antineoplaston A10; antineoplaston AS2-1

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Primary Malignant Brain Tumors.
antineoplaston A10; antineoplaston AS2-1

Brain and Central Nervous System Tumors Clinical Trial using adjuvant therapy; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years to 70 years.
- Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study.
adjuvant therapy; radiation therapy

Medulloblastoma, Brain Tumors, or Neuroectodermal Tumors, Primiti Clinical Trial using Etoposide, carboplatin, melphalan, cisplatin, thiotepa

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting N/A to 10 years.
- Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy.
Etoposide, carboplatin, melphalan, cisplatin, thiotepa